Loading…
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition
Background Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, cli...
Saved in:
Published in: | International journal of clinical oncology 2020-02, Vol.25 (2), p.217-239 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043 |
---|---|
cites | cdi_FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043 |
container_end_page | 239 |
container_issue | 2 |
container_start_page | 217 |
container_title | International journal of clinical oncology |
container_volume | 25 |
creator | Mishima, Saori Taniguchi, Hiroya Akagi, Kiwamu Baba, Eishi Fujiwara, Yutaka Hirasawa, Akira Ikeda, Masafumi Maeda, Osamu Muro, Kei Nishihara, Hiroshi Nishiyama, Hiroyki Takano, Tadao Tsuchihara, Katsuya Yatabe, Yasushi Kodera, Yasuhiro Yoshino, Takayuki |
description | Background
Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. In Japan, a PD-1 inhibitor for dMMR advanced solid tumors, regardless of the primary tumor site, has been approved. However, there are some issues related to administering immune checkpoint inhibitors in the clinical practice setting, making it necessary to develop the guidelines.
Methods
Clinical questions (CQs) regarding medical care were formulated for patients with dMMR advanced solid tumors, and evidence to the CQs was collected by manual search to prepare recommendations. Then, the committee members voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other factors.
Results
The current guideline, which we consider a provisional clinical opinion at this point, describes the 11 requirements to be considered in terms of patients for whom dMMR testing is recommended, the timing and methods of dMMR testing, and clinical care systems required to perform dMMR testing properly and to administer immune checkpoint inhibitors safely.
Conclusion
This provisional clinical opinion proposes the requirements for performing dMMR testing properly to select patients who are likely to benefit from immune checkpoint inhibitors and administering them safely. |
doi_str_mv | 10.1007/s10147-019-01498-8 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6989445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2254522240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEoqXwAizQldiwaMB_cZINUjW0_KjQBbC2HMeZcZXYqZ0U5Xl5Ee7MtKVlwSKKnXvu53Odk2UvKXlLCSnfJUqoKHNCa3xEXeXVo-yQCl7mZVmyx7jmgua1ZMVB9iylS0JoKQv2NDvglFWSVfVh9vuLHrWH78E4Oy0QOlj1zjuje7jwJvRhvcAYw7VLLnj8aG6rYcRF8NCFCNPGQuv02ofkEmjfwpzsluWGYfYBy1GPCzgPo56c9VOCX27aQGs7Z7Z7-PDtBAaXBj2ZDUQ7aofUeQgxHYMJYUTAZFtoFtj5tYi_Z_mrbR84PoYzF9MEp62b0OPz7Emn-2Rf3LyPsp9npz9Wn_Lzi4-fVyfnucHLm3JumWxISXhDrdSN6UxRCk5by22nCasFKUQruS6kqGrRSWu4pl0ny6ahjSCCH2Xv99xxbgbbGhws6l6N0Q06Lipopx5WvNuodbhWskagKBDw5gYQw9Vs06TwTozte5w4zEkxVoiCMSYISl__I70Mc8Q_tFNxKQokoortVSaGlKLt7sxQorYZUvsMKcyQ2mVIVdj06v4Ydy23oUEB3wsSlvzaxr9n_wf7B1UK2Gk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2253645944</pqid></control><display><type>article</type><title>Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition</title><source>Springer Link</source><creator>Mishima, Saori ; Taniguchi, Hiroya ; Akagi, Kiwamu ; Baba, Eishi ; Fujiwara, Yutaka ; Hirasawa, Akira ; Ikeda, Masafumi ; Maeda, Osamu ; Muro, Kei ; Nishihara, Hiroshi ; Nishiyama, Hiroyki ; Takano, Tadao ; Tsuchihara, Katsuya ; Yatabe, Yasushi ; Kodera, Yasuhiro ; Yoshino, Takayuki</creator><creatorcontrib>Mishima, Saori ; Taniguchi, Hiroya ; Akagi, Kiwamu ; Baba, Eishi ; Fujiwara, Yutaka ; Hirasawa, Akira ; Ikeda, Masafumi ; Maeda, Osamu ; Muro, Kei ; Nishihara, Hiroshi ; Nishiyama, Hiroyki ; Takano, Tadao ; Tsuchihara, Katsuya ; Yatabe, Yasushi ; Kodera, Yasuhiro ; Yoshino, Takayuki</creatorcontrib><description>Background
Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. In Japan, a PD-1 inhibitor for dMMR advanced solid tumors, regardless of the primary tumor site, has been approved. However, there are some issues related to administering immune checkpoint inhibitors in the clinical practice setting, making it necessary to develop the guidelines.
Methods
Clinical questions (CQs) regarding medical care were formulated for patients with dMMR advanced solid tumors, and evidence to the CQs was collected by manual search to prepare recommendations. Then, the committee members voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other factors.
Results
The current guideline, which we consider a provisional clinical opinion at this point, describes the 11 requirements to be considered in terms of patients for whom dMMR testing is recommended, the timing and methods of dMMR testing, and clinical care systems required to perform dMMR testing properly and to administer immune checkpoint inhibitors safely.
Conclusion
This provisional clinical opinion proposes the requirements for performing dMMR testing properly to select patients who are likely to benefit from immune checkpoint inhibitors and administering them safely.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-019-01498-8</identifier><identifier>PMID: 31286289</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Cancer Research ; Clinical trials ; DNA repair ; Immune checkpoint inhibitors ; Immunotherapy ; Medicine ; Medicine & Public Health ; Mismatch repair ; Oncology ; Patients ; PD-1 protein ; Solid tumors ; Special ; Special Article ; Surgical Oncology ; Survival ; Tumors</subject><ispartof>International journal of clinical oncology, 2020-02, Vol.25 (2), p.217-239</ispartof><rights>The Author(s) 2019</rights><rights>International Journal of Clinical Oncology is a copyright of Springer, (2019). All Rights Reserved. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043</citedby><cites>FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31286289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mishima, Saori</creatorcontrib><creatorcontrib>Taniguchi, Hiroya</creatorcontrib><creatorcontrib>Akagi, Kiwamu</creatorcontrib><creatorcontrib>Baba, Eishi</creatorcontrib><creatorcontrib>Fujiwara, Yutaka</creatorcontrib><creatorcontrib>Hirasawa, Akira</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Maeda, Osamu</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>Nishihara, Hiroshi</creatorcontrib><creatorcontrib>Nishiyama, Hiroyki</creatorcontrib><creatorcontrib>Takano, Tadao</creatorcontrib><creatorcontrib>Tsuchihara, Katsuya</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><creatorcontrib>Kodera, Yasuhiro</creatorcontrib><creatorcontrib>Yoshino, Takayuki</creatorcontrib><title>Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. In Japan, a PD-1 inhibitor for dMMR advanced solid tumors, regardless of the primary tumor site, has been approved. However, there are some issues related to administering immune checkpoint inhibitors in the clinical practice setting, making it necessary to develop the guidelines.
Methods
Clinical questions (CQs) regarding medical care were formulated for patients with dMMR advanced solid tumors, and evidence to the CQs was collected by manual search to prepare recommendations. Then, the committee members voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other factors.
Results
The current guideline, which we consider a provisional clinical opinion at this point, describes the 11 requirements to be considered in terms of patients for whom dMMR testing is recommended, the timing and methods of dMMR testing, and clinical care systems required to perform dMMR testing properly and to administer immune checkpoint inhibitors safely.
Conclusion
This provisional clinical opinion proposes the requirements for performing dMMR testing properly to select patients who are likely to benefit from immune checkpoint inhibitors and administering them safely.</description><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>DNA repair</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mismatch repair</subject><subject>Oncology</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Solid tumors</subject><subject>Special</subject><subject>Special Article</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Tumors</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9ks1u1DAUhSMEoqXwAizQldiwaMB_cZINUjW0_KjQBbC2HMeZcZXYqZ0U5Xl5Ee7MtKVlwSKKnXvu53Odk2UvKXlLCSnfJUqoKHNCa3xEXeXVo-yQCl7mZVmyx7jmgua1ZMVB9iylS0JoKQv2NDvglFWSVfVh9vuLHrWH78E4Oy0QOlj1zjuje7jwJvRhvcAYw7VLLnj8aG6rYcRF8NCFCNPGQuv02ofkEmjfwpzsluWGYfYBy1GPCzgPo56c9VOCX27aQGs7Z7Z7-PDtBAaXBj2ZDUQ7aofUeQgxHYMJYUTAZFtoFtj5tYi_Z_mrbR84PoYzF9MEp62b0OPz7Emn-2Rf3LyPsp9npz9Wn_Lzi4-fVyfnucHLm3JumWxISXhDrdSN6UxRCk5by22nCasFKUQruS6kqGrRSWu4pl0ny6ahjSCCH2Xv99xxbgbbGhws6l6N0Q06Lipopx5WvNuodbhWskagKBDw5gYQw9Vs06TwTozte5w4zEkxVoiCMSYISl__I70Mc8Q_tFNxKQokoortVSaGlKLt7sxQorYZUvsMKcyQ2mVIVdj06v4Ydy23oUEB3wsSlvzaxr9n_wf7B1UK2Gk</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Mishima, Saori</creator><creator>Taniguchi, Hiroya</creator><creator>Akagi, Kiwamu</creator><creator>Baba, Eishi</creator><creator>Fujiwara, Yutaka</creator><creator>Hirasawa, Akira</creator><creator>Ikeda, Masafumi</creator><creator>Maeda, Osamu</creator><creator>Muro, Kei</creator><creator>Nishihara, Hiroshi</creator><creator>Nishiyama, Hiroyki</creator><creator>Takano, Tadao</creator><creator>Tsuchihara, Katsuya</creator><creator>Yatabe, Yasushi</creator><creator>Kodera, Yasuhiro</creator><creator>Yoshino, Takayuki</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200201</creationdate><title>Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition</title><author>Mishima, Saori ; Taniguchi, Hiroya ; Akagi, Kiwamu ; Baba, Eishi ; Fujiwara, Yutaka ; Hirasawa, Akira ; Ikeda, Masafumi ; Maeda, Osamu ; Muro, Kei ; Nishihara, Hiroshi ; Nishiyama, Hiroyki ; Takano, Tadao ; Tsuchihara, Katsuya ; Yatabe, Yasushi ; Kodera, Yasuhiro ; Yoshino, Takayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>DNA repair</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mismatch repair</topic><topic>Oncology</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Solid tumors</topic><topic>Special</topic><topic>Special Article</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mishima, Saori</creatorcontrib><creatorcontrib>Taniguchi, Hiroya</creatorcontrib><creatorcontrib>Akagi, Kiwamu</creatorcontrib><creatorcontrib>Baba, Eishi</creatorcontrib><creatorcontrib>Fujiwara, Yutaka</creatorcontrib><creatorcontrib>Hirasawa, Akira</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Maeda, Osamu</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>Nishihara, Hiroshi</creatorcontrib><creatorcontrib>Nishiyama, Hiroyki</creatorcontrib><creatorcontrib>Takano, Tadao</creatorcontrib><creatorcontrib>Tsuchihara, Katsuya</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><creatorcontrib>Kodera, Yasuhiro</creatorcontrib><creatorcontrib>Yoshino, Takayuki</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mishima, Saori</au><au>Taniguchi, Hiroya</au><au>Akagi, Kiwamu</au><au>Baba, Eishi</au><au>Fujiwara, Yutaka</au><au>Hirasawa, Akira</au><au>Ikeda, Masafumi</au><au>Maeda, Osamu</au><au>Muro, Kei</au><au>Nishihara, Hiroshi</au><au>Nishiyama, Hiroyki</au><au>Takano, Tadao</au><au>Tsuchihara, Katsuya</au><au>Yatabe, Yasushi</au><au>Kodera, Yasuhiro</au><au>Yoshino, Takayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>25</volume><issue>2</issue><spage>217</spage><epage>239</epage><pages>217-239</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. In Japan, a PD-1 inhibitor for dMMR advanced solid tumors, regardless of the primary tumor site, has been approved. However, there are some issues related to administering immune checkpoint inhibitors in the clinical practice setting, making it necessary to develop the guidelines.
Methods
Clinical questions (CQs) regarding medical care were formulated for patients with dMMR advanced solid tumors, and evidence to the CQs was collected by manual search to prepare recommendations. Then, the committee members voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other factors.
Results
The current guideline, which we consider a provisional clinical opinion at this point, describes the 11 requirements to be considered in terms of patients for whom dMMR testing is recommended, the timing and methods of dMMR testing, and clinical care systems required to perform dMMR testing properly and to administer immune checkpoint inhibitors safely.
Conclusion
This provisional clinical opinion proposes the requirements for performing dMMR testing properly to select patients who are likely to benefit from immune checkpoint inhibitors and administering them safely.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31286289</pmid><doi>10.1007/s10147-019-01498-8</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1341-9625 |
ispartof | International journal of clinical oncology, 2020-02, Vol.25 (2), p.217-239 |
issn | 1341-9625 1437-7772 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6989445 |
source | Springer Link |
subjects | Cancer Research Clinical trials DNA repair Immune checkpoint inhibitors Immunotherapy Medicine Medicine & Public Health Mismatch repair Oncology Patients PD-1 protein Solid tumors Special Special Article Surgical Oncology Survival Tumors |
title | Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A24%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japan%20Society%20of%20Clinical%20Oncology%20provisional%20clinical%20opinion%20for%20the%20diagnosis%20and%20use%20of%20immunotherapy%20in%20patients%20with%20deficient%20DNA%20mismatch%20repair%20tumors,%20cooperated%20by%20Japanese%20Society%20of%20Medical%20Oncology,%20First%20Edition&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Mishima,%20Saori&rft.date=2020-02-01&rft.volume=25&rft.issue=2&rft.spage=217&rft.epage=239&rft.pages=217-239&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-019-01498-8&rft_dat=%3Cproquest_pubme%3E2254522240%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c498t-3e26b0703b1e6abcfc57431de3efa0294054d63a564894f6ec3a1ff67bb1b4043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2253645944&rft_id=info:pmid/31286289&rfr_iscdi=true |